Valproate semisodium - AbbVie
Alternative Names: [14C]-Sodium Valproate; Depakote; Depakote ER; Divalproex; Divalproex sodium; Divalproex sodium DR 500mg tablets - Abbott Laboratories; Epival; Epival ER; LA40220Latest Information Update: 05 Nov 2023
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; Sanofi
- Class Antiepileptic drugs; Antimanics; Antimigraines; Pentanoic acids; Small molecules
- Mechanism of Action Enzyme inhibitors; GABA agents; GABA modulators; Voltage-gated sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bipolar disorders; Epilepsy; Migraine
- Discontinued Dementia
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in United Kingdom (PO, Powder)
- 14 Apr 2021 Discontinued - Phase-III for Dementia (In the elderly, In adults) in USA (PO)
- 11 Apr 2019 Sanofi completes a phase I trial in Epilepsy (In volunteers) in United Kingdom (PO) (NCT03681158)